• Explore /
  • Poster
  • / Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study.

Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study.

Abstract Poster

Authors

null

Min-Hee Ryu

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Min-Hee Ryu , Young Iee Park , Ik-Joo Chung , Keun-Wook Lee , Ho-Suk Oh , Kyung Hee Lee , Hye Sook Han , Bong-Gun Seo , Jae-Cheol Jo , Hyo Rak Lee , Sook Ryun Park , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT01671449

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4015)

DOI

10.1200/JCO.2016.34.15_suppl.4015

Abstract #

4015

Poster Bd #

7

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

First Author: Ali Fawaz

First Author: Yuhong Dai

First Author: Weijian Guo

First Author: Yasuhide Yamada